Comparative safety and costs of stepping down asthma medications in patients with controlled asthma

Authors:

Abstract
No abstract available
Funding Information
  • Genentech (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • Agency for Healthcare Research and Quality (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • National Center for Advancing Translational Sciences (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • National Institutes of Health (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • GlaxoSmithKline (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • Agency for Healthcare Research and Quality (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • Novartis (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • Mayo Clinic (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)
  • National Center for Advancing Translational Sciences (TL1 TR000137, R03 HS-22126, R03 HS-22126, TL1 TR000137)

This publication has 14 references indexed in Scilit: